Axovant Sciences (AXON), vTv Therapeutics (VTVT) Mechanisms Don't Overlap with Sola - Piper
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Baird Sees Minimal Read Through for Axovant (AXON) on Lilly's Sola Failure
November 23, 2016 12:26 PM ESTBaird analyst Brian Skorney came out to defend Axovant Sciences (NYSE: AXON), which was weaker on Lilly's solanezumab failure. The analyst sees no change for AXON and maintained an Outperform rating and price target of $29.
Skorney commented, "The Alzheimer's field was... More
Axovant Sciences (AXON) Sinks 17% on Eli Lilly Sola Failure
November 23, 2016 7:50 AM ESTAxovant Sciences (NYSE: AXON) is down 17% in pre-open trade after Eli Lilly & Co. (NYSE: LLY) announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... MoreAxovant Sciences (AXON): Allergan Acquisition of Chase a Positive - Baird
November 23, 2016 6:36 AM ESTBaird analyst, Brian Skorney, reiterated his Outperform rating on shares of Axovant Sciences (NYSE: AXON) after Allergan (NYSE: AGN) announced the acquisition of Chase Pharmaceuticals, a privately held company focusing on development of fixed-dose combinations in... More
